RadNet Acquires Gleamer, Bolstering AI Leadership in Radiology
Event summary
- RadNet acquired Gleamer SAS, a Paris-based radiology AI company, for up to €230 million.
- Gleamer achieved an Annual Recurring Revenue (ARR) compound annual growth rate exceeding 90% from 2022 through 2025, expected to reach approximately $30 million ARR in 2026.
- The acquisition integrates Gleamer into RadNet’s DeepHealth subsidiary, positioning it as the largest provider of radiology clinical AI solutions globally.
- DeepHealth, combined with Gleamer, now supports 26 FDA-cleared and 22 CE-marked devices supporting 75+ indications.
The big picture
The acquisition underscores the growing importance of AI in radiology, driven by radiologist shortages and increasing imaging volumes. RadNet’s move to acquire Gleamer, a fast-growing European player, signals a strategic shift towards consolidating leadership in the clinical AI space, a market poised for significant expansion as healthcare providers seek to automate workflows and improve patient outcomes. The €230 million valuation reflects the high demand for AI solutions in radiology and the potential for substantial recurring revenue.
What we're watching
- Integration Risk
- The success of this acquisition hinges on RadNet’s ability to effectively integrate Gleamer’s operations and technology into DeepHealth, particularly given the cultural differences between a US-based and a European company.
- Market Adoption
- The pace at which RadNet can deploy Gleamer’s solutions across its network and achieve the promised cost efficiencies and productivity gains will determine the acquisition’s ROI.
- Competitive Landscape
- How DeepHealth will navigate the increasingly competitive landscape of radiology AI, especially with larger players potentially entering the market, will be crucial for sustaining its leadership position.
Related topics